Chemotherapy Treatment Guidelines for Cervical Cancer

Treatment Overview

The American College of Oncology recommends surgery as the primary treatment for early-stage cervical cancer, with chemotherapy reserved for adjuvant therapy only in patients with high-risk pathologic features 1
For high-risk patients post-surgery, adjuvant concurrent chemoradiotherapy with weekly cisplatin 40 mg/m² is recommended, with a strength of evidence level I, A 1, 4

For stage IA1, conization or simple hysterectomy is standard, with chemotherapy not indicated unless lymph node involvement is found, as per the National Comprehensive Cancer Network guidelines 1, 2
For stage IA2-IB1, radical hysterectomy with lymph node dissection is preferred, with adjuvant chemoradiotherapy reserved for high-risk features, according to the American College of Oncology 1, 3
For locally advanced cervical cancer, concurrent chemoradiotherapy with weekly cisplatin 40 mg/m² is the standard of care, demonstrating an absolute 5-year survival benefit of 8% for overall survival, as recommended by the European Society for Medical Oncology 1, 4, 5

The standard chemoradiotherapy regimen includes weekly cisplatin 40 mg/m² during external beam radiation therapy, with a strength of evidence level I, A, as per the National Cancer Institute guidelines 1, 3, 5
Radiation therapy should be high-dose (80-90 Gy to target) delivered over a short duration (<50-55 days), including external beam plus brachytherapy, according to the American Society for Radiation Oncology 5, 6

For metastatic or recurrent cervical cancer, paclitaxel and cisplatin combined with bevacizumab is the preferred first-line regimen, with a strength of evidence level I, A, as recommended by the American College of Oncology 1, 4
The preferred regimen is paclitaxel + cisplatin + bevacizumab 15 mg/kg every 3 weeks, with a strength of evidence level I, A, according to the European Society for Medical Oncology 1